While no evidence has been presented for how frequently an interaction between virions and endogenous sACE2 happens in COVID-19 patients, a case study showed that intravenous infusion of human recombinant soluble ACE2 (hrsACE2) could successfully treat severe COVID-19 (124); the putative mechanism behind this treatment may involve preventing SARS-CoV-2 from entering ACE2-expressing cells for replication and thereby-reducing angiotensin-II levels in the circulation. This evidence concerns the gene AGT and COVID-19.